Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report on November 4, 2008, to announce its financial and operating results for the third quarter ended September 30, 2008. While the 8-K itself does not contain the detailed financial figures, it references a press release (Exhibit 99.1) that was issued on the same date, which provides the specific results. Investors should refer to the press release attached as Exhibit 99.1 for comprehensive details on Regeneron's financial performance and operational achievements during the third quarter of 2008. This filing serves as the official notification of the release of these results, indicating the company's ongoing commitment to timely disclosure of material information.
Key Highlights
- 1Form 8-K filed on November 4, 2008, reporting on the company's third quarter 2008 financial and operating results.
- 2The 8-K report indicates that the detailed financial and operating results were disclosed in a press release issued on November 4, 2008.
- 3The press release, dated November 4, 2008, is included as Exhibit 99.1 to the 8-K filing.
- 4Item 2.02 of the 8-K, Results of Operations and Financial Condition, is the primary section referencing the release of quarterly results.
- 5This filing is a standard notification mechanism for the public dissemination of quarterly performance data.
- 6Investors are directed to the referenced press release for specific financial figures and operational updates.